The cardiopulmonary reserve index is an effective predictor of prognosis in patients with pulmonary hypertension, particularly when pulmonary hypertension is caused by left heart disease.
Combination treatment with ambrisentan and tadalafil is associated with a reduced mortality risk profile in patients with scleroderma-associated pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension, factors that affect prognosis but not treatment response included age, gender, and connective tissue disease-PAH etiology.
Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with pneumonia and patients with an acute IPF exacerbation.
Investigators substantiated strategies to encourage approval rates for proprotein convertase subtilisin/kexin type 9 inhibitors.
Investigators assessed the risk for herpes zoster and provided recommendations regarding treatment in patients with psoriasis.
There is a high prevalence of discordance in the reduction of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) in response to evolocumab treatment.
Dapagliflozin reduces MACE, CV death, and risk for heart failure hospitalization in patients with type 2 diabetes and prior MI.
The American College of Cardiology and American Heart Association have released a new evidence-based guideline detailing the primary prevention of cardiovascular disease.
This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019. SAN FRANCISCO — Patients…
